吉非替尼治疗晚期非小细胞肺癌的临床观察  

The effects of gefitinib on the advanced non-small cell lung cancer patients

作　　者：袁彬 王岗 吴敏慧 禇亮 赵征 吕云 袁媛 施常备 

机构地区：[1]陕西省肿瘤医院,陕西西安710061

出　　处：《现代肿瘤医学》2010年第4期720-722,共3页Journal of Modern Oncology

摘　　要：目的:研究吉非替尼对晚期非小细胞肺癌(NSCLC)的疗效。方法:收集13例晚期NSCLC患者,口服吉非替尼250mg/d,直到病情进展或因不良反应不能耐受为止,观察其疗效及不良反应。结果:21例中部分缓解(PR)10例,稳定(SD)7例,进展(PD)4例,缓解率47.6%,疾病控制率80.9%。结论:吉非替尼治疗晚期NSCLC患者有一定疗效,不良反应轻。Objective：To evaluate the efficacy and safety of gefitinib on patients with advanced non-small cell lung cancer.Methods：Thirteen advanced non-small lung patients received gefitinib 250mg/d,qd,until disease progression or occurrence of intolerable toxicity.Results： Among 13 patients,no one got complete response,7 patients got partial response,4 patients were stable,and 2 patients developed.The totle reponse rate was 47.6%,disease control rate was 80.9%.Conclusion：Gefitinib is effective and safe in treatment of patients with advanced NSCLC.

关 键 词：非小细胞肺癌 吉非替尼 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]